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Abstract 
Cachexia
 
is a relevant comorbid condition of chronic diseases including cancer. 
Inflammation, oxidative stress, autophagy, ubiquitin-proteasome system, nuclear factor (NF)-
κB, and mitogen activated protein kinases (MAPK) are involved in the pathophysiology of 
cancer cachexia. Currently available treatment is limited and data demonstrating effectiveness 
in in vivo models are lacking. Our objectives were to explore in respiratory and limb muscles 
of lung cancer (LC) cachectic mice whether proteasome, NF-κB, and MAPK inhibitors 
improve muscle mass and function loss through several molecular mechanisms. Body and 
muscle weights, limb muscle force, protein degradation and the ubiquitin-proteasome system, 
signaling pathways, oxidative stress and inflammation, autophagy, contractile and functional 
proteins, myostatin and myogenin, and muscle structure were evaluated in the diaphragm and 
gastrocnemius of LC (LP07 adenocarcinoma) bearing cachectic mice (BALB/c), with and 
without concomitant treatment with NF-κB (sulfasalazine), MAPK (U0126), and proteasome 
(bortezomib) inhibitors. Compared to control animals, in both respiratory and limb muscles of 
LC cachectic mice: muscle proteolysis, ubiquitinated proteins, autophagy, myostatin, protein 
oxidation, FoxO-1, NF-κB and MAPK signaling pathways, and muscle abnormalities were 
increased, while myosin, creatine kinase, myogenin, and slow- and fast-twitch muscle fiber 
size were decreased. Pharmacological inhibition of NF-κB and MAPK, but not the 
proteasome system, induced in cancer cachectic animals, a substantial restoration of muscle 
mass and force through a decrease in muscle protein oxidation and catabolism, myostatin, and 
autophagy, together with a greater content of myogenin, and contractile and functional 
proteins. Attenuation of MAPK and NF-κB signaling pathway effects on muscles is beneficial 
in cancer-induced cachexia.   
Key words:  
● cancer-induced cachexia  
● skeletal muscles  
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● proteolysis  
●
 autophagy  
● oxidative stress and inflammation  
● muscle structure and function  
● proteasome, NF-κB, and MAPK inhibitors 
 
 
INTRODUCTION 
Muscle wasting and cachexia
 
are important systemic manifestations of highly prevalent 
conditions including cancer. The prevalence of cachexia varies across diseases, but in 
advanced malignancies it ranges from 60 to 80% (von and Anker, 2010), being greater in 
patients with lung and gastrointestinal tumors than in other solid or hematologic malignancies 
(Muscaritoli et al, 2006). Cachexia, characterized by muscle mass loss and body composition 
alterations, has a negative impact on the patients’ quality of life (Evans et al, 2008).  
Although the etiology of cancer-induced cachexia remains to be fully understood, several 
cellular and molecular mechanisms have been proposed such as systemic 
inflammation(Argiles et al, 2011), oxidative stress (Barreiro et al, 2005;Barreiro et al, 
2009;Marin-Corral et al, 2010;Mastrocola et al, 2008), metabolic disturbances and nutritional 
abnormalities(Barreiro et al, 2005;Barreiro et al, 2009;Morley et al, 2010). The myostatin and 
activin IIB system is also a relevant proposed mechanism contributing to muscle protein 
catabolism. Indeed, it was clearly demonstrated that the soluble receptor antagonist of 
myostatin (sActRIIB) improved muscle mass loss, survival and physical activity in cancer 
cachectic rodents (Busquets et al, 2012;Zhou et al, 2010). Furthermore, mitogen-activated 
protein kinases (MAPK) and nuclear factor (NF)-κB, which are central regulators of gene 
expression, redox balance, and metabolism, have also been shown to play a major role in 
adaptive or maladaptive responses to cellular stress within skeletal muscles (Kramer and 
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Goodyear, 2007). MAPK activation also seems to mediate oxidative stress-induced muscle 
atrophy (McClung et al, 2010). Interestingly, MAPK signaling was also shown to be involved 
in enhanced expression of proteasome via proteolysis-inducing factor in C2C12 myotubes 
(Smith and Tisdale, 2003). However, studies demonstrating the potential beneficial effects of 
MAPK inhibition in cancer-induced cachexia in vivo are lacking.  
NF-κB was also demonstrated to participate in the process of muscle wasting under 
several conditions such as sepsis (Penner et al, 2001), cancer cachexia (Cai et al, 2004;Moore-
Carrasco et al, 2007), and chronic obstructive pulmonary disease (COPD) (Agusti et al, 
2004;Moore-Carrasco et al, 2007). In fact, the double NF-κB and AP-1 inhibitor SP100030 
elicited an improvement in muscle weights and markers of the ubiquitin-proteasome system 
(Moore-Carrasco et al, 2007). Sulfasalazine, a well-known drug used for the treatment of 
patients with inflammatory bowel disease and rheumatoid arthritis, is a potent and specific 
inhibitor of NF-κB. It inhibits its translocation into the nucleus, without affecting the 
activation of the AP-1 transcription factor (Wahl et al, 1998). Furthermore, that inhibition is 
accompanied by a blockade of the degradation of its inhibitory subunit IκB(Wahl et al, 1998). 
Sulfasalazine was also shown to restore tissue injury and function in several experimental 
models (Camara-Lemarroy et al, 2009;Olmez et al, 2008). However, the potential beneficial 
effects of NF-κB inhibition using sulfasalazine on cancer-induced cachexia are still unknown.  
The ubiquitin-proteasome system plays a major role in conditions characterized by 
muscle wasting and weakness (Argiles and Lopez-Soriano, 1996;Fermoselle et al, 
2011;Fermoselle et al, 2012;Olmez et al, 2008;Roth et al, 2005;van Hees et al, 2008;van et al, 
2011). Specifically, bortezomib, the first proteasome inhibitor approved for use in patients, 
was demonstrated to significantly restore diaphragm muscle contractile function and myosin 
heavy chain content (MyHC) following coronary heart failure (van Hees et al, 2008) and 
elastase-induced emphysema(van et al, 2011). In another investigation (Supinski et al, 2009), 
however, bortezomib failed to improve the endotoxin-induced diaphragm dysfunction, while 
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partially restoring enhanced protein catabolism. Whether inhibition of the proteasome restores 
muscle mass and function in cancer cachexia remains to be identified.  
As treatment options for cachexia are extremely limited and in vivo studies demonstrating 
the effectiveness of several potential anti-cachectic agents are clearly lacking, the current 
investigation was specifically designed to explore whether inhibitors of relevant cellular 
pathways such as MAPK, NF-κB, and the proteasome exert beneficial therapeutic effects on 
muscle mass loss and force generation in an in vivo experimental model of lung cancer 
cachexia in mice. Moreover, research conducted so far has mostly focused on the evaluation 
of limb muscles. On this basis, our objectives were to assess in respiratory and limb muscles 
from lung cancer (LC) cachectic mice receiving concomitant treatment with either MAPK, 
NF-κB, or proteasome inhibitors: 1) body and muscle weights, 2) limb muscle force, 3) 
proteolysis markers, 4) signaling pathways, 5) oxidative stress (protein carbonylation and 
nitration and antioxidant enzymes) and proinflammatory cytokines such as tumor necrosis 
factor (TNF)-alpha, interferon-gamma, interleukin (IL)-1beta and IL-6, 6) autophagy, 7) 
contractile and functional proteins, 8) myostatin and myogenin levels, and 9) muscle 
structural alterations.  
 
MATERIALS AND METHODS 
(See the supplementary online material for additional information on all methodologies). 
Animal experiments 
Tumor. LP07 cell line, which was previously obtained in vitro after successive passages of a 
P07 primary culture (Urtreger et al, 2001), derives from the transplantable P07 lung tumor 
that appeared spontaneously in the lung of a BALB/c mouse(Diament et al, 1998). LP07 cell 
line shares identical characteristics regarding lung tumor incidence and histology, and 
cachexia with its parental P07 tumor(Diament et al, 1998;Diament et al, 2006;Urtreger et al, 
2001). Female BALB/c mice, 2 months old (weight ~20g), were obtained from Harlan 
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Interfauna Ibérica SL (Barcelona, Spain).  
Experimental design. In all experimental groups (except for control rodents), LP07 viable 
cells (4·105) resuspended in 0.2 mL minimal essential media (MEM) were subcutaneously 
inoculated in the left flank of the mice (day 1). All groups (n=10/group) were studied for a 
period of one month. Animals were randomly assigned to the following groups: 1) control, 
inoculation of 0.2 mL MEM in the left flank; 2) LC cachexia group, inoculation of LP07 
cells; 3) LC cachectic mice received concomitant treatment with the proteasome inhibitor 
Bortezomib (Velcade, Millenium Pharmaceuticals, Cambridge, MA), 0.15 mg/Kg, 0.1 mL/6 
days, intravenous injection into the tail vein (LC cachectic-bortezomib group) (Lu et al, 
2006); 4) LC cachectic mice received concomitant treatment with sulfasalazine (Pfizer, 
Madrid, Spain), 200 mg/Kg, 0.3 mL/48h, intraperitoneal injection (LC cachectic-NF-κB 
inhibitor group) (Olmez et al, 2008); and 5) LC cachectic mice received concomitant 
treatment with the MAPK inhibitor
 
U0126 (a highly selective inhibitor of MAP/ERK kinase 
(MEK)1/2 proteins, Selleck chemicals, Houston, TX), 30 mg/Kg, 0.1 mL/48h, intraperitoneal 
injection (LC cachectic-MAPK inhibitor group) (Schuh and Pahl, 2009). For ethical reasons, 
all pharmacological therapies were administered on day 15 after the inoculation of the LP07 
cells up until the end of the study period (day 30). In order to assess the level of NF-κB 
transcription and ex-vivo protein degradation using the luciferase reporter and the tyrosine 
release assays, respectively (see below), a second batch of mice experiments was also 
conducted on identical experimental groups (N=10/group). One hind-limb and half of the 
diaphragm were used for each type of these experiments.  
Ethics. All animal experiments were conducted in the animal facilities at Parc de Recerca 
Biomèdica de Barcelona (PRBB, Spain). This controlled study was designed in accordance 
with both the ethical standards on animal experimentation (EU 609/86 CEE, Real Decreto 
1201/05 BOE 252, Spain) at PRBB
 
and the European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other Scientific Purposes (1986). Ethical 
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approval was obtained by the Animal Research Committee at the Catalan Government 
(Animal welfare department, EBP-09-1228).  
In vivo measurements and sample collection from mice 
Body weight and food intake were determined every day during the entire duration of the 
study. Food and water were supplied ad libitum for the entire duration of the study protocol in 
the tumor-bearing mice. Control animals were paired-fed according to the amount of food 
eaten by the cachectic rodents. Limb strength was determined on days 0 and 30 using a 
strength grip meter (Bioseb, Chaville, France) following previously published methodologies, 
in which grip strength was also the end-point parameter in several experimental models of 
cancer cachexia in mice (Barreiro et al, 2010a;Murphy et al, 2012;Toledo et al, 2011;Vignaud 
et al, 2010;Whittemore et al, 2003). In the LC cachexia group of mice, tumor progression was 
determined using positron emission tomography (PET) (Figure E1) on days 13 and 20. Mice 
from all the experimental groups were always sacrificed on day 30 post-inoculation of LP07 
cells or MEM (control animals). Each mouse was inoculated intraperitoneally with 0.1 mL 
sodium pentobarbital (60 mg/Kg). Diaphragm and gastrocnemius muscles and the 
subcutaneous tumor were obtained from all animals (Figure E2). The weight of both muscles 
and tumor was determined in each animal using a high-precision scale. Frozen tissues were 
used for immunoblotting and enzyme-linked immunosorbent assay (ELISA) techniques, while 
paraffin-embedded tissues were used for the assessment of muscle structure abnormalities and 
fiber type morphometry. 
Muscle biology analyses 
All muscle biology analyses were conducted blind in the same laboratory by the same 
investigators, at Hospital del Mar-IMIM (Barcelona). 
Immunoblotting of 1D electrophoresis. Protein levels of the different molecular markers 
analyzed in the study were explored by means of immunoblotting procedures as previously 
described (Barreiro et al, 2010b;Barreiro et al, 2012;Fermoselle et al, 2011;Fermoselle et al, 
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2012;Marin-Corral et al, 2010). Protein content of markers of proteolysis, signaling pathways 
of muscle atrophy, redox balance, and different muscle proteins were identified using specific 
primary antibodies (See detailed information in the online supplementary material).  
Protein catabolism. Protein degradation was explored on the basis of the rate of production of 
free tyrosine from tissue proteins as previously described (Tischler et al, 1982). As muscles 
cannot synthesize or degrade this amino acid, its accumulation reflects the net degradation of 
proteins. The results were expressed as nmol of tyrosine/mg of muscle/2 hours of incubation.  
Luciferase reporter gene assay. On day 23 of the animal protocol (7 days exactly before 
sacrifice) all mice were injected in the right gastrocnemius muscle (for obvious reasons the 
diaphragm was not used for this purpose) with a mixture of 15 µg of control plasmid pRL-TK 
vector, which contains a cDNA encoding renilla luciferase (Promega Corporation, Madison, 
WI, USA) and 20 µg of reporter plasmid pNF-κB-Luc, which contains the firefly luciferase 
gene (Clonetech, Mountain View, CA, USA). The procedures followed have already been 
published (McClung et al, 2010). 
Cytokine Enzyme-linked Immunosorbent Assay (ELISA). Protein levels of the cytokines tumor 
necrosis factor (TNF)-alpha, interferon-gamma, interleukin (IL)-6 and IL-1beta were 
quantified in the muscles of all study animals (diaphragms and gastrocnemius muscles) using 
specific sandwich ELISA kits eBiosience, Bender MedSystems, Vienna, Austria) following 
previously published methodologies (Barreiro et al, 2008;Barreiro et al, 2010b;Fermoselle et 
al, 2012).  
Muscle fiber counts and morphometry. On 3-micrometer muscle paraffin-embedded sections 
from diaphragms and gastrocnemius muscles of all study groups, morphometrical analyses 
were performed as previously reported (Barreiro et al, 2010b;Barreiro et al, 2011;Fermoselle 
et al, 2012).   
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Muscle structure abnormalities. The area fraction of normal and abnormal muscle was 
evaluated on 3-micrometer paraffin-embedded sections of the diaphragm and gastrocnemius 
of all study groups following previously published methodologies (Figure E3) (Barreiro et al, 
2010b;Barreiro et al, 2011;Fermoselle et al, 2012).  
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. In 
muscle paraffin-embedded sections, apoptotic nuclei were identified using the TUNEL assay 
(In Situ Cell Death Detection Kit, POD, Roche Applied Science, Mannheim, Germany) in 
both diaphragms and gastrocnemius muscles from all study groups following precisely the 
manufacturer’s instructions and previously published studies (Barreiro et al, 2011).  
Statistical Analysis 
Results are presented as mean (SD). Comparisons of physiological and biological variables 
among the different study groups were analyzed using one-way analysis of variance. For the 
purpose of the study two different sets of comparisons were made: i) control and LC 
cachectic mice, and on the other hand ii) LC cachectic and LC cachectic-bortezomib, iii) LC 
cachectic and LC cachectic-NF-κB inhibitor; and iv) LC cachectic and LC cachectic-MAPK 
inhibitor. Tukey’s post hoc analysis was used to adjust for multiple comparisons. Statistical 
significance corresponding to these two different sets of comparisons is being specifically 
indicated in both Figures and Tables. Correlations between physiological and biological 
variables were explored using the Pearson’s correlation coefficient. The sample size chosen 
was based on previous studies, where very similar approaches were employed (Barreiro et al, 
2005;Barreiro et al, 2008;Barreiro et al, 2010b;Barreiro et al, 2011;Barreiro et al, 
2012;Busquets et al, 2012;Diament et al, 2006;Fermoselle et al, 2011;Fermoselle et al, 
2012;Marin-Corral et al, 2010;Muscaritoli et al, 2006;Penna et al, 2010;Testelmans et al, 
2010;Troosters et al, 2010;Vogiatzis et al, 2010)  and on assumptions of 80% power to detect 
an improvement of more than 20% in measured outcomes at a level of significance of P≤ 
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0.05. In most of the biological variables, mean difference between groups was initially 
estimated at a minimum of 20-25% and standard deviation was approximately 25-30% of the 
mean value for each of the variables. 
 
 
 
 
RESULTS 
Physiological characteristics 
As shown in Table 1 and Figure 1, at the end of the study period (day 30), LC cachectic mice 
exhibited a reduction in body weight gain that was not observed in control animals. Food 
intake was similar among the study groups (3 g/24h). Diaphragm and gastrocnemius muscle 
weights and limb strength gain were significantly reduced in the LC cachectic mice compared 
to control rodents (Table 1). On day 15 (treatment period start point), mice did not show any 
statistically significant difference in body weight among the study groups (Table E1). LC 
cachectic mice treated with the NF-κB and MAPK inhibitors exhibited a significantly smaller 
reduction in weight gain, a significant improvement in diaphragm and gastrocnemius weight 
loss, and a significant recovery of muscle strength gain compared to the non-treated cachectic 
animals (Table 1). The progression of body weight during the study period for all the mouse 
groups is shown in Figure 1. The proteasome inhibitor did not induce any significant effects 
on body or muscle weights, or limb muscle strength in the LC cachectic mice (Table 1 and 
Figure 1). Importantly, the weight of the subcutaneous tumor was significantly reduced in the 
cachectic rodents treated with the inhibitors of the proteasome (18%), NF-κB (27%), and 
MAPK (60%) pathways compared to non-treated cachectic mice (Table 1).  
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Muscle proteolysis 
Tyrosine release. Protein degradation, as measured by the release of the amino acid tyrosine, 
was increased in both diaphragm and gastrocnemius muscles of LC cachectic mice compared 
to controls (Figure 2A). Interestingly, treatment of cachectic mice with bortezomib, NF-κB, 
and MAPK inhibitor induced a significant reduction in tyrosine release levels in both 
respiratory and limb muscles (Figure 2A).  
Proteolytic systems. The diaphragm muscle, but not gastrocnemius, of LC cachectic mice 
exhibited a significant increase in protein levels of calpain compared to controls (Table E2, 
Figure E4). The inhibitors of NF-κB and MAPK pathways elicited a significant reduction in 
calpain content only in the diaphragm of cachectic mice, while bortezomib did not induce any 
significant effect in any muscle (Table E2, Figure E4). Levels of the ubiquitin-conjugating 
enzyme E214κ were increased only in the gastrocnemius of cachectic mice compared to 
controls (Figures 2B and E5). Importantly, inhibitors of proteasome, NF-κB, and MAPK 
pathways significantly decreased levels of E214k in the gastrocnemius, but not the diaphragm, 
of cachectic mice (Figures 2B and E5).  Levels of the E3 ligases atrogin-1 and MURF-1 did 
not differ in any muscle of the study groups (Table E2, Figures E6 and E7). Protein content of 
20S proteasome subunit C8 did not differ between LC cachectic and control mice (Figure 2C, 
top panel, and Figure E8). As expected, bortezomib induced a significant reduction, 
especially in gastrocnemius, in protein content of subunit C8 among cachectic animals, while 
NF-κB and MAPK inhibitors did not elicit any significant modification (Figure 2C, top panel, 
and Figure E8).  Protein ubiquitination levels were significantly greater in both respiratory 
and limb muscles of LC cachectic mice than in controls (Figure 2C, bottom panel, and Figure 
E9). In cachectic mice, bortezomib induced a significant reduction in protein ubiquination in 
both diaphragm and gastrocnemius, whereas NF-κB and MAPK inhibitors elicited a decrease 
in that proteolytic marker only in limb muscles (Figure 2C, bottom panel and Figure E9). 
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Signaling pathways of muscle proteolysis 
FoxO pathway. While total content of FoxO-1 did not differ in any muscle between cachectic 
and control mice, content of p-FoxO-1 was significantly greater in gastrocnemius of cachectic 
rodents than in controls (Table E2 and Figures E10 and E11, respectively). Bortezomib 
induced a reduction in total FoxO-1 content, but not p-FoxO-1, only in cachectic diaphragms, 
whereas NF-κB and MAPK inhibitors did not elicit any modification in muscle content of 
either total or active FoxO-1 (Table E2 and Figures E10 and E11, respectively). 
MAPK pathway. Muscle levels of MAPK subfamilies ASK1, ERK1/2, p-ERK1/2, JNK, and 
p-p38 did not differ between LC cachectic and control mice (Table E2 and Figures E12, E13, 
E14, E15, and E16, respectively). However, levels of total p38 were significantly greater in 
both diaphragm and gastrocnemius in cachectic mice than in controls (Table E2 and Figure 
E17). Interestingly, treatment of cachectic animals with MAPK inhibitor elicited a significant 
reduction in protein levels of ERK1/2, p-ERK1/2, and total p38 in respiratory and limb 
muscles (Table E2 and Figures E13, E14, and E17, respectively).  
NF-κB pathway. In respiratory and limb muscles, protein content of p50 and p-p50 was 
significantly increased in cachectic animals compared to controls (Figures 3A, top and bottom 
panels, and Figures E18, and E19). A significant decrease was observed in total p50 in both 
diaphragm and gastrocnemius of cachectic mice in response to proteasome, NF-κB, and 
MAPK inhibitors, while p-p50 levels were only reduced in both muscles among animals 
treated with the NF-κB inhibitor controls (Figures 3A, top and bottom panels, and Figures 
E18, and E19). Total protein content of p65, but not p-p65, were increased in diaphragms and 
gastrocnemius of cachectic mice compared to controls (Figure 3B, top and bottom panels, and 
Figures E20 and E21). A significant reduction was detected in protein content of p65 in both 
respiratory and limb muscles of cachectic rodents in response to proteasome and NF-κB 
inhibitors, while p-p65 protein levels were decreased only in response to NF-κB inhibitor in 
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those muscles (Figure 3B, top and bottom panels, respectively, and Figures E20 and E21). 
Protein levels of total IκB and p-IκB were significantly diminished in both diaphragms and 
gastrocnemius muscles in cachectic mice compared to controls (Figure 3C top and bottom 
panels, and Figures E22 and E23). Interestingly, treatment of cachectic rodents with 
proteasome, NF-κB, and MAPK inhibitors elicited an increase in both total IκB and p-IκB 
markers in respiratory (except for MAPK inhibitor) and limb muscles Figure 3C top and 
bottom panels, respectively, and Figures E22 and E23). Transcriptional activity of NF-κB 
was increased in cachectic mice compared to controls (Figure 3D). Importantly, among 
cachectic rodents, treatment with both proteasome and NF-κB inhibitors elicited a significant 
decline in NF-κB transcriptional activity, while no differences were observed in response to 
MAPK inhibition (Figure 3D). 
Muscle growth and differentiation. In cachectic mice, protein levels of myostatin were 
increased in both diaphragms and gastrocnemius compared to control rodents (Figures 4A and 
E24). Importantly, proteasome, NF-κB, and MAPK inhibitors elicited a significant reduction 
in myostatin levels in muscles of cachectic animals (Figures 4A, top panel, and E24). 
Nevertheless, compared to controls, protein content of myogenin was significantly reduced 
within respiratory and limb muscles of cachectic rodents, while treatment with either NF-κB 
or MAPK inhibitors, but not bortezomib, elicited a rise in myogenin content in their muscles 
(Figures 4A, bottom panel, and E25).  
Contractile and functional muscle proteins 
Protein levels of contractile MyHC were reduced in diaphragm and gastrocnemius of 
cachectic mice compared to controls (Figure 4B, top panel). Interestingly, NF-κB and MAPK 
inhibitors, but not bortezomib, elicited an improvement in MyHC protein content in 
respiratory and limb muscles among cachectic rodents (Figures 4B, top panel, and E26). 
Protein content of skeletal muscle actin did not differ among any of the study groups (Figures 
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4B, bottom panel, and E27). Compared to controls, creatine kinase protein content was 
significantly reduced only in gastrocnemius of tumor-bearing animals (Table E2 and Figure 
28). Treatment of these mice with proteasome, NF-κB, and MAPK inhibitors induced a rise 
in creatine kinase content only in limb muscles (Table E2 and Figure E28). No differences 
were detected in carbonic anhydrase-3 muscle levels among the study groups (Table E2 and 
Figures E29).  
Muscle inflammation and redox balance  
Inflammatory cytokines. ELISA levels of interferon-gamma were only significantly increased 
in diaphragms of cachectic mice compared to controls (Table E2). TNF-alpha, IL-6, and IL-
1beta ELISA levels did not differ between cachectic and control mice (Table E2). Treatment 
with bortezomib elicited a significant decline in protein levels of interferon-gamma, TNF-
alpha, IL-6, and IL-1beta in gastrocnemius of cachectic rodents (Table E2). Protein content of 
the studied cytokines was not different in any muscles of cachectic animals in response to 
NF-κB inhibition (Table E2). Diaphragm levels of interferon-gamma, TNF-alpha, and IL-6 
were decreased among cachectic rodents treated with MAPK inhibitor (Table E2). 
Oxidative stress markers. Compared to controls, protein carbonylation levels were 
significantly increased in both diaphragms and gastrocnemius muscles of cachectic mice 
(Table E2 and Figure E30). Treatment of these rodents with proteasome, NF-κB, and MAPK 
inhibitors elicited a reduction in total protein carbonylation in respiratory and limb muscles 
(Table E2 and Figure E30). HNE-protein adduct levels were increased only in gastrocnemius 
of tumor-bearing mice compared to controls, and treatment with proteasome, NF-κB, and 
MAPK inhibitors did not induce any significant effect on their muscles (Table E2 and Figure 
E31). Muscle protein tyrosine nitration levels did not differ among the study groups (Table 
E2 and Figure E32).  
Antioxidant enzymes. Compared to control rodents, protein levels of SOD2 were decreased in 
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diaphragms and gastrocnemius of tumor-bearing mice, and treatment with proteasome, NF-
κB, and MAPK inhibitors elicited a significant rise in SOD2 content only in gastrocnemius 
(Table E2 and Figure E33). Muscle protein content of CuZn-SOD and catalase did not differ 
among study groups (Table E2, and Figures E34 and E35, respectively).  
Muscle autophagy 
Muscle protein levels of the autophagy system p62 and beclin-1 did not differ among the 
study groups (Table E2, and Figures E36 and E37). Protein levels of LC3 as measured by the 
ratio of LC3-II to LC3-I, however, were significantly increased in diaphragm and 
gastrocnemius of cachectic mice compared to controls (Figures 5 and E38), and treatment 
with proteasome, NF-κB, or MAPK inhibitors elicited a significant decline in LC3II/LC in 
diaphragms and gastrocnemius of tumor-bearing mice (Figures 5 and E38). 
Muscle structure  
Fiber type composition. Proportions of type I and type II fibers were not different in any 
muscle among the study groups (Table 2). Compared to controls, the size of slow- and fast-
twitch fibers was significantly diminished in both diaphragm and gastrocnemius of cachectic 
mice (Table 2 and Figures 6A and 6B). In these animals, treatment with either proteasome or 
MAPK inhibitors, but not NF-κB inhibitor, elicited a significant improvement in sizes of type 
I fibers in both muscles (Table 2 and Figures 6A and 6B).   
Muscle abnormalities. Compared to control mice, proportions of abnormal muscle were 
greater in both diaphragms and gatrocnemius of cachectic animals (Table 2). In these animals, 
treatment with MAPK inhibitor elicited a significant reduction in total muscle abnormalities 
only in the limb muscle, while inducing a decrease in inflammatory cell proportions in both 
muscles (Table 2). Compared to controls, TUNEL-stained nuclei counts were increased in 
both diaphragms and gastrocnemius of cachectic mice (Table 2 and Figures 6C and 6D). 
Importantly, only treatment of these animals with MAPK inhibitor induced a significant 
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decrease in proportions of TUNEL-stained nuclei in their diaphragms (Table 2 and Figures 
6C and 6D). 
 
 
 
 
DISCUSSION 
In BALB/c mice, subcutaneous inoculation of LP07 cells induced lung metastases, together 
with a severe cachexia that was accompanied by a significant decline in the diaphragm and 
limb muscle mass and strength generation (Urtreger et al, 2001). Despite that a recent 
investigation (Roberts et al, 2013) elegantly showed that colon-26 cancer cachexia is 
characterized by diaphragm muscle structure and function impairment in mice, we believe 
that the current findings on proteolysis, signaling pathways, and structural alterations add 
insight into current knowledge on how several muscle types are affected in the process of 
muscle wasting. Moreover, it also sheds light on the predominant role of MAPK and NF-κB 
signaling in the process of muscle wasting, which could be targeted with pharmacological 
agents. In fact, knowledge on the treatment of muscle wasting is still at its infancy and 
additional confirmatory studies are needed, especially in cancer cachexia, which is further 
impaired by chemotherapy (Garcia et al, 2013;Hajjaji et al, 2012;Xue et al, 2011). Previous 
investigations showed that nutrition modulation using several nutrients (Hajjaji et al, 
2012;Xue et al, 2011) and ghrelin (Garcia et al, 2013) may prevent body weight loss in cancer 
patients undergoing chemotherapy. Moreover, the metabolic modulator trimetazidine was also 
shown to activate protein synthesis signaling, while decreasing E3 ligase and myostatin levels 
in experimental models (Ferraro et al, 2013). The current study focuses on the assessment of 
the effects of several inhibitors of key cellular pathways in experimental cancer-induced 
cachexia.  
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In line with the study hypothesis, the main findings in the investigation were that 
compared to control animals, in both respiratory and limb muscles of LC cachectic mice: 1) 
muscle proteolysis was enhanced; 2) total amounts of ubiquitinated proteins and autophagy 
were increased; 3) calpain levels were higher only in the diaphragm; 4) myostatin levels were 
greater, while those of myogenin were reduced; 5) protein creatine kinase levels were 
decreased only in the gastrocnemius; 6) levels of contractile MyHC were reduced, while those 
of actin were not modified; 7) the size of slow- and fast-twitch muscle fibers was decreased in 
both muscles, while proportions of muscle abnormalities and TUNEL-stained nuclei were 
increased; 8) protein oxidation levels were greater, whereas inflammatory cytokine levels 
were not modified; and 9) signaling pathways such as FoxO-1, NF-κB, and MAPK were 
increased. Treatment of LC cachectic mice with the pharmacological inhibitors induced 
several modifications that are discussed below.  
Pharmacological proteasome inhibition in cancer cachectic muscles 
Proteasome, an energy-dependent proteolytic system, is a key modulator of cellular processes 
including NF-κB signaling and is also involved in cell metabolism and DNA repair. Among 
the different pharmacological proteasome inhibitors described so far, bortezomib is currently 
the only agent approved for clinical use in patients with cancer(Cvek and Dvorak, 2007). 
Proteasome also seems to play a major role in the muscle mass loss and dysfunction process 
associated with several chronic conditions(Supinski et al, 2009;van Hees et al, 2008;van et al, 
2011) and severe infections(Roth et al, 2005).  
In the current investigation, although cachectic mice treated with bortezomib exhibited a 
significantly lower tumor size compared to non-treated tumor-bearing rodents, body and 
muscle weights together with limb muscle force did not improve. In fact, only an 
improvement in the size of slow-twitch fibers, but not type II, was observed in either 
respiratory or limb muscles in response to proteasome inhibition. Besides, no significant 
modifications in contractile MyHC or actin contents were detected in any muscle. These 
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findings are in agreement with those reported in a previous study conducted in endotoxemic 
rats (Supinski et al, 2009), in which treatment with several proteasome inhibitors prevented 
muscle proteolysis, but not diaphragm muscle loss or force generation. Nevertheless, the 
present findings and those previously reported (Supinski et al, 2009), are counter to results 
demonstrated in other two investigations, in which contractile diaphragm function was shown 
to improve in response to bortezomib in rats bearing congestive heart failure (van Hees et al, 
2008) and emphysema (van et al, 2011).  
One likely explanation to account for differences encountered among studies (Supinski et 
al, 2009;van Hees et al, 2008;van et al, 2011) is that different proteolytic systems other than 
the proteasome may participate in reduced body weight, and decreased muscle mass and 
weakness under several experimental conditions. In line with this, it was demonstrated 
(Fareed et al, 2006;Supinski and Callahan, 2006) that other proteases such as caspase and 
calpain (not modified by bortezomib in any muscle) need to be initially activated within the 
myocytes in order to break down the contractile myofilaments under muscle wasting 
conditions. Moreover, the proteasome inhibitor seems to have rather prevented proteolysis 
(lower tyrosine release levels and tumor sizes) of non-contractile proteins (cytosolic or 
nuclear proteins), which may account for the lack of significant improvements observed in 
limb muscle function, and in both myofibrilar protein and muscle mass loss in this 
experimental model of cancer cachexia. Another explanation accounting for the failure of 
bortezomib to improving muscle mass or function in the cachectic mice is the lack of effects 
of the proteasome inhibitor on muscle protein synthesis. This pathway is likely to be reduced 
in the muscles of the cachectic mice, as was shown to occur in other models of cancer-
induced cachexia (Robert et al, 2012). However, the present investigation was not designed to 
explore protein anabolism in the mouse cachectic muscles.  Another interesting finding in the 
investigation was the reduction in protein content of the 20S proteasome subunit in both 
respiratory and limb muscles in response to bortezomib, which was not induced by the other 
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agents. It is likely that chronic administration (15 days) of the proteasome inhibitor may also 
induce and effect not only on proteasome activity but also on its content.  
Pharmacological NF-κB inhibition in cancer cachectic muscles 
NF-κB modulates the expression of cytokines, growth factors, and a wide variety of genes 
that regulate physiological and pathological conditions. NF-κB is one of the most relevant 
signaling pathways leading to skeletal muscle loss. It is composed by a family of five 
members (p65, Rel-B, c-Rel, p50, and p52), which are all expressed within skeletal muscles. 
The NF-κB dimers RelA (p65) and NF-κB1 (p50) are sequestered in an active cytoplasmic 
complex by binding to its inhibitory subunit IκB. Following the stimulus, IκB becomes 
phosphorylated by specific kinases. This phosphorylation entails ubiquitination and fast 
degradation of IκB by the proteasome. Free NF-κB dimers translocate to the nucleus and 
activate target genes. Sulfasalazine was shown to be a powerful and specific NF-κB inhibitor 
by essentially inhibiting NF-κB-dependent transcription in several models (Camara-Lemarroy 
et al, 2009;Olmez et al, 2008;Wahl et al, 1998).  
In the current investigation, it has been clearly demonstrated that NF-κB pathway was 
upregulated in both respiratory and limb muscles of LC cachectic mice. In those muscles, 
sulfasalazine elicited a significant decline in protein levels of total and phosphorylated p65 
and p50 members, while inducing a substantial upregulation of IκB and p-IκB among the 
cachectic rodents. Moreover, in the present experimental model, these findings were further 
confirmed by experiments performed to specifically assess NF-κB transcriptional activity. In 
this regard, NF-κB activity was increased in diaphragm and gastrocnemius muscles of 
cachectic mice, whereas the activity was specifically downregulated in response to both 
proteasome and NF-κB inhibition, especially the latter. These are interesting findings which 
suggest that NF-κB plays a crucial role in cancer-induced cachexia signaling in this 
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experimental model of cancer cachexia.   
Importantly, treatment of the cachectic mice with sulfasalazine also elicited other 
interesting modifications in muscles of the cachectic rodents. In this respect, a substantial 
improvement was seen in body and muscle weights, limb muscle strength, and tumor size 
(27% decrease), together with a reduction in muscle protein degradation and oxidation, E214κ 
and protein ubiquitination levels, myostatin content, and autophagy as measured by LC3-
II/LC3-I levels. Additionally, in muscles of tumor-bearing mice treated with sulfasalazine, a 
significant increase in myogenin, contractile MyHC, and creatine kinase content, was also 
observed in response to NF-κB inhibition. Protein levels of SOD2 were also increased in the 
limb muscles, but not the diaphragm, of the cachectic mice in response to sulfasalazine. These 
findings are counter to previous studies in which NF-κB activity was shown to induce SOD2 
expression (Rui and Kvietys, 2005;Sundaramoorthy et al, 2013). Differences in the 
experimental models and cell types may account for discrepancies between the studies (Rui 
and Kvietys, 2005;Sundaramoorthy et al, 2013). No significant modifications, however, were 
seen in fiber sizes or muscle cytokine content, whose levels were, indeed, similar to those 
observed in the muscles of the non-treated cachectic and control animals. This is somehow 
counter to previous reports (Peterson et al, 2011), in which NF-κB and TNF-alpha were 
shown to signal muscle atrophy. Moreover, it is likely that NF-κB pathway predominantly 
regulates apoptosis and nonimmune autophagy in multinucleated cells as shown in other 
models (Alger et al, 2011). This observation may account for the lack of improvement 
observed in the muscle fibers sizes in response to NF-κB pathway inhibition in the cachectic 
mice (Alger et al, 2011). 
Body and muscle weight and strength improvement in response to NF-κB inhibition was 
likely to be achieved through the contribution of several factors such as reduced levels of 
protein degradation, myostatin, and autophagy, and increased myogenin content, which may 
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have led, in turn, to higher content of contractile MyHC in the cachectic muscles. Myostatin, 
which is almost exclusively expressed in skeletal muscles, is a potent negative regulator of 
muscle mass. The increase in myostatin levels observed in the cachectic muscles are in line 
with previous reports, in which significant increases in myostatin content were shown in 
diaphragm and gastrocnemius of emphysema cachectic mice (Fermoselle et al, 2011), in 
muscles of cachectic COPD patients (Fermoselle et al, 2012;Testelmans et al, 2010;Troosters 
et al, 2010;Vogiatzis et al, 2010), and in cancer patients (Aversa et al, 2012). A thorough 
assessment of the myostatin and activin IIB system was not the focus of the current research. 
Nonetheless, previous investigations have clearly demonstrated that the sActRIIB led to an 
improvement in muscle mass loss, exercise, and survival in cachectic mice (Busquets et al, 
2012;Zhou et al, 2010).  
Myogenin plays an important role in skeletal muscle differentiation, maintenance and 
repair, regulating muscle metabolism and energy utilization. Levels of myogenin were 
decreased in muscles of the cachectic mice, while NF-κB restored those levels in both 
muscles. These findings are in keeping with a previous investigation (Fermoselle et al, 
2012;Testelmans et al, 2010;Troosters et al, 2010;Vogiatzis et al, 2010), in which myogenin 
levels were also decreased in cachectic severe COPD patients. Another aspect that deserves 
attention is the smaller size of the subcutaneous tumor in response to NF-κB inhibition among 
the LC cachectic mice. However, the present investigation was not designed to disentangle 
the potential relationships between tumor size and the degree of cachexia in the animals.  
Pharmacological MAPK inhibition in cancer cachectic muscles 
MAPK cascade leads to the activation of protein kinases and transcription factors through 
phosphorylation, resulting in signal transduction, hence playing a key role in cell signaling. In 
the current study, both total and phosphorylated protein content of the best characterized 
MAPK subfamilies ERK1/2, p38, JNK, and ASK1 was explored in the muscles of all groups 
of mice. Total p38, but not p-p38, levels were increased in both respiratory and limb muscles 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
22 
 
of tumor-bearing rodents. Importantly, MAPK inhibition elicited a significant improvement in 
body and muscle weight gain, limb strength, proteolysis and protein ubiquitination levels, 
especially in the gastrocnemius. These findings are in line with a recent investigation in which 
muscle mass loss was restored by inhibiting ERK activity in colon cancer mice (Penna et al, 
2010).  
MAPK inhibition was confirmed by the significant decrease in protein content of both 
total and phosphorylated ERK1/2 in respiratory and limb cachectic muscles. Additionally, 
MAPK inhibitor elicited a significant decrease in p38 protein content in diaphragm and limb 
muscles of tumor-bearing rodents. Importantly, inhibition of MAPK pathway also induced 
other interesting findings in the cachectic animals such as an increase in myogenin content 
together with a reduction in myostatin levels, a substantial rise in contractile MyHC in both 
diaphragm and gastrocnemius, an increase in creatine kinase protein in the limb muscle, and a 
decrease in protein oxidation and autophagy levels in both muscles. Interestingly, from a 
structural standpoint, cachectic mice treated with MAPK inhibitor also exhibited larger slow-
twitch muscle fibers in diaphragm and gastrocnemius along with a decrease in the percentage 
of muscle structural abnormalities.  
Taken together, these findings suggest that MAPK pathway controls muscle proteolysis 
through the ubiquitin-proteasome and autophagy systems in both respiratory and limb 
muscles of cancer cachectic mice. Other mechanisms involved in the regulation of muscle 
mass such as myostatin and myogenin were also modulated by the effect of MAPK inhibitor 
in the cachectic muscles. Finally, an interesting finding in the current study is the substantial 
reduction in tumor size (60%) observed in tumor-bearing mice treated with the MAPK 
inhibitor. As abovementioned, a significant reduction in tumor size might have also 
contributed to attenuating the cachectic effects in the muscles of the treated mice. We do not 
believe, however, that this phenomenon has been a relevant contributor in the investigation 
for the following reason. The effects of NF-κB inhibition on the size of the subcutaneous 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
23 
 
tumor were smaller compared to those elicited by MAPK inhibitor and relatively similar to 
those elicited by bortezomib, while a greater modulation of body weight and muscle mass and 
force development was achieved in response to NF-κB than to MAPK or proteasome 
inhibitions. Future studies may be designed in order to specifically address to what extent 
tumor size and regulation by pharmacological agents contribute to muscle wasting and 
weakness in cancer-induced cachexia.  
Finally, another relevant finding in the investigation was the increased protein oxidation 
levels encountered in respiratory and limb cachectic muscles. Inhibition of proteasome, NF-
κB, and MAPK activities elicited a significant decline in protein carbonylation in diaphragm 
and gastrocnemius muscles. Indeed, NF-κB and MAPK activation seem to play a relevant role 
in the transcriptional regulation of redox balance within muscles, while also mediating 
oxidative stress-induced muscle atrophy (McClung et al, 2010;Powers et al, 2005). 
Study limitations and future perspectives 
A first limitation is related to the lack of measurements on the tumor size throughout 
the entire duration of the protocol in the tumor-bearing animals. In the study, tumor weights 
were only available at the time of sacrifice in all experimental groups. Another limitation has 
to do with the lack of specific functional data on the diaphragm muscle. However, a first step 
in this field of investigation was to explore whether molecular and cellular events involved in 
muscle wasting also take place in the main respiratory muscle in an experimental model of 
cancer cachexia. Besides, a previous study already showed that muscle contractile function 
was severely affected in another model of cachexia in mice (Roberts et al, 2013).  
Additionally, the reduction in tumor burden observed in the cachectic rodents in 
response to treatment with the pharmacological inhibitors could have also influenced the 
molecular events found in the muscles. In this regard, tumor growth as measured by ki-67 
(cell proliferation marker) decreased in the cachectic mice treated with any of the inhibitors 
(data not shown). Future investigations should elucidate to what extent these specific 
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inhibitors partly act via a reduction in tumor burden and growth or mostly exert a direct effect 
on the muscle fibers.  
Despite the relevance of the current findings in the attenuation of muscle wasting, 
results should be taken cautiously in clinical settings of patients with cancer cachexia, as the 
studied pharmacological agents may also exert effects on other tissues and organs. The 
identification of more tissue-specific inhibitors or selective devices to deliver the drugs to the 
target organs warrants further research.  
Finally, it should be mentioned that exercise capacity, physical activity, or fatigue 
resistance may additionally provide valuable information in this specific model of LC 
cachexia despite that they were not explored in the current study. However, previous 
investigations based on the utilization of similar models of cancer cachexia, limb muscle 
strength was indeed the main physiological end-point (Murphy et al, 2012;Toledo et al, 
2011;Whittemore et al, 2003). In summary, several questions remain unanswered, which will 
have to be addressed in future studies aimed to explore those specific issues in experimental 
models of cachexia.  
Conclusions 
We conclude from the present experimental model of LC-induced cachexia that NF-κB and 
MAPK are predominant signaling pathways. Pharmacological inhibition of NF-κB and 
MAPK, but not the proteasome system, induced in cancer cachectic animals, a substantial 
restoration of muscle mass and force through a decrease in muscle protein oxidation and 
catabolism, myostatin, and autophagy, together with a greater content in myogenin, and 
contractile and functional proteins. Attenuation of MAPK and NF-κB signaling pathways 
exerts beneficial effects on muscles in cancer-induced cachexia, thus offering potential new 
therapeutic strategies for this condition.   
 
 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
25 
 
ACKNOWLEDGMENTS 
The authors are thankful to Dr. Xavier Mateu for his help and advice with the 
pharmacological inhibitors, Dr. Juan Martin-Caballero for his assistance with part of the 
animal experiments, and Mr. Francisco Sanchez, Mrs. Mònica Vilà-Ubach and Ariadna 
Estivill-Pérez for their technical support with part of the animal and molecular biology 
experiments.  
 
CONFLICT OF INTEREST 
The authors declare no conflict of interest in relation to this study.  
 
 
 
 
 
 
 
Literature Cited 
 
Agusti A, Morla M, Sauleda J, Saus C, Busquets X (2004). NF-kappaB activation and iNOS 
upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59:483-
487. 
Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, Ghimbovschi S, Chen YW, 
Lundberg IE, Nagaraju K (2011). The role of TRAIL in mediating autophagy in myositis 
skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum 
63:3448-3457. 
Argiles JM, Busquets S, Lopez-Soriano FJ (2011). Anti-inflammatory therapies in cancer 
cachexia. Eur J Pharmacol 668 Suppl 1:S81-S86. 
Argiles JM, Lopez-Soriano FJ (1996). The ubiquitin-dependent proteolytic pathway in 
skeletal muscle: its role in pathological states. Trends Pharmacol Sci 17:223-226. 
Aversa Z, Bonetto A, Penna F, Costelli P, Di RG, Lacitignola A, Baccino FM, Ziparo V, 
Mercantini P, Rossi FF, Muscaritoli M (2012). Changes in myostatin signaling in non-weight-
losing cancer patients. Ann Surg Oncol 19:1350-1356. 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
26 
 
Barreiro E, de la PB, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM (2005). Both oxidative 
and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett 
579:1646-1652. 
Barreiro E, Del Puerto-Nevado L, Puig-Vilanova E, Perez-Rial S, Sanchez F, Martinez-Galan 
L, Rivera S, Gea J, Gonzalez-Mangado N, Peces-Barba G (2012). Cigarette smoke-induced 
oxidative stress in skeletal muscles of mice. Respir Physiol Neurobiol 182:9-17. 
Barreiro E, Ferrer D, Sanchez F, Minguella J, Marin-Corral J, Martinez-Llorens J, Lloreta J, 
Gea J (2011). Inflammatory cells and apoptosis in respiratory and limb muscles of patients 
with COPD. J Appl Physiol 111:808-817. 
Barreiro E, Garcia-Martinez C, Mas S, Ametller E, Gea J, Argiles JM, Busquets S, Lopez-
Soriano FJ (2009). UCP3 overexpression neutralizes oxidative stress rather than nitrosative 
stress in mouse myotubes. FEBS Lett 583:350-356. 
Barreiro E, Marin-Corral J, Sanchez F, Mielgo V, Alvarez FJ, Galdiz JB, Gea J (2010a). 
Reference values of respiratory and peripheral muscle function in rats. J Anim Physiol Anim 
Nutr (Berl) 94:e393-e401. 
Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sanchez F, Gea J, Barbera JA 
(2010b). Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary 
disease skeletal muscle dysfunction. Am J Respir Crit Care Med 182:477-488. 
Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J 
(2008). Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 63:100-
107. 
Busquets S, Toledo M, Orpi M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, Lopez-
Soriano FJ, Han HQ, Argiles JM (2012). Myostatin blockage using actRIIB antagonism in 
mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and 
physical performance. J Cachexia Sarcopenia Muscle 3:37-43. 
Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera 
WR, Lee J, Glass DJ, Shoelson SE (2004). IKKbeta/NF-kappaB activation causes severe 
muscle wasting in mice. Cell 119:285-298. 
Camara-Lemarroy CR, Guzman-de la Garza FJ, Alarcon-Galvan G, Cordero-Perez P, 
Fernandez-Garza NE (2009). Effect of sulfasalazine on renal ischemia/reperfusion injury in 
rats. Ren Fail 31:822-828. 
Cvek B, Dvorak Z (2007). Targeting of nuclear factor-kappaB and proteasome by 
dithiocarbamate complexes with metals. Curr Pharm Des 13:3155-3167. 
Diament MJ, Garcia C, Stillitani I, Saavedra VM, Manzur T, Vauthay L, Klein S (1998). 
Spontaneous murine lung adenocarcinoma (P07): A new experimental model to study 
paraneoplastic syndromes of lung cancer. Int J Mol Med 2:45-50. 
Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM 
(2006). Inhibition of tumor progression and paraneoplastic syndrome development in a 
murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer 
Invest 24:126-131. 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
27 
 
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh 
K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, 
Rossi FF, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008). 
Cachexia: a new definition. Clin Nutr 27:793-799. 
Fareed MU, Evenson AR, Wei W, Menconi M, Poylin V, Petkova V, Pignol B, Hasselgren 
PO (2006). Treatment of rats with calpain inhibitors prevents sepsis-induced muscle 
proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul 
Integr Comp Physiol 290:R1589-R1597. 
Fermoselle C, Rabinovich R, Ausin P, Puig-Vilanova E, Coronell C, Sanchez F, Roca J, Gea 
J, Barreiro E (2012). Does oxidative stress modulate limb muscle atrophy in severe COPD 
patients? Eur Respir J 40:851-862. 
Fermoselle C, Sanchez F, Barreiro E (2011). [Reduction of muscle mass mediated by 
myostatin in an experimental model of pulmonary emphysema]. Arch Bronconeumol 47:590-
598. 
Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni 
W, Berghella L, Rosano G (2013). The metabolic modulator trimetazidine triggers autophagy 
and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J 280:5094-5108. 
Garcia JM, Scherer T, Chen JA, Guillory B, Nassif A, Papusha V, Smiechowska J, Asnicar 
M, Buettner C, Smith RG (2013). Inhibition of cisplatin-induced lipid catabolism and weight 
loss by ghrelin in male mice. Endocrinology 154:3118-3129. 
Hajjaji N, Couet C, Besson P, Bougnoux P (2012). DHA effect on chemotherapy-induced 
body weight loss: an exploratory study in a rodent model of mammary tumors. Nutr Cancer 
64:1000-1007. 
Kramer HF, Goodyear LJ (2007). Exercise, MAPK, and NF-kappaB signaling in skeletal 
muscle. J Appl Physiol 103:388-395. 
Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS 
(2006). Investigation of drug-drug interaction potential of bortezomib in vivo in female 
Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos 34:702-
708. 
Marin-Corral J, Fontes CC, Pascual-Guardia S, Sanchez F, Olivan M, Argiles JM, Busquets 
S, Lopez-Soriano FJ, Barreiro E (2010). Redox balance and carbonylated proteins in limb and 
heart muscles of cachectic rats. Antioxid Redox Signal 12:365-380. 
Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, Aragno M, 
Costelli P (2008). Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative 
stress. Free Radic Biol Med 44:584-593. 
McClung JM, Judge AR, Powers SK, Yan Z (2010). p38 MAPK links oxidative stress to 
autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 
298:C542-C549. 
Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, Argiles JM 
(2007). The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
28 
 
experimental cancer cachexia. Int J Oncol 30:1239-1245. 
Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, 
Ferrucci L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K, 
Muscaritoli M, Ponikowski P, Posthauer ME, Rossi FF, Schambelan M, Schols AM, Schuster 
MW, Anker SD (2010). Nutritional recommendations for the management of sarcopenia. J 
Am Med Dir Assoc 11:391-396. 
Murphy KT, Chee A, Trieu J, Naim T, Lynch GS (2012). Importance of functional and 
metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. 
Dis Model Mech 5:533-545. 
Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi FF (2006). Prevention and 
treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42:31-41. 
Olmez D, Babayigit A, Uzuner N, Erbil G, Karaman O, Yilmaz O, Cetin EO, Ozogul C 
(2008). Efficacy of sulphasalazine on lung histopathology in a murine model of chronic 
asthma. Exp Lung Res 34:501-511. 
Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, Costelli P (2010). Muscle 
wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. 
PLoS One 5:e13604. 
Penner CG, Gang G, Wray C, Fischer JE, Hasselgren PO (2001). The transcription factors 
NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem 
Biophys Res Commun 281:1331-1336. 
Peterson JM, Bakkar N, Guttridge DC (2011). NF-kappaB signaling in skeletal muscle health 
and disease. Curr Top Dev Biol 96:85-119. 
Powers SK, Kavazis AN, DeRuisseau KC (2005). Mechanisms of disuse muscle atrophy: role 
of oxidative stress. Am J Physiol Regul Integr Comp Physiol 288:R337-R344. 
Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, Tremblay ML, Gallouzi IE, 
Hekimi S, Wing SS, Pelletier J (2012). Targeting protein synthesis in a Myc/mTOR-driven 
model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 
72:747-756. 
Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, Powers SK, Fuller DD, 
Ferreira LF, Judge AR (2013). Diaphragm and ventilatory dysfunction during cancer 
cachexia. FASEB J 27:2600-2610. 
Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim 
E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ (2005). Heightened levels of 
circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35:399-403. 
Rui T, Kvietys PR (2005). NFkappaB and AP-1 differentially contribute to the induction of 
Mn-SOD and eNOS during the development of oxidant tolerance. FASEB J 19:1908-1910. 
Schuh K, Pahl A (2009). Inhibition of the MAP kinase ERK protects from 
lipopolysaccharide-induced lung injury. Biochem Pharmacol 77:1827-1834. 
Smith HJ, Tisdale MJ (2003). Signal transduction pathways involved in proteolysis-inducing 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
29 
 
factor induced proteasome expression in murine myotubes. Br J Cancer 89:1783-1788. 
Sundaramoorthy S, Ryu MS, Lim IK (2013). B-cell translocation gene 2 mediates crosstalk 
between PI3K/Akt1 and NFkappaB pathways which enhances transcription of MnSOD by 
accelerating IkappaBalpha degradation in normal and cancer cells. Cell Commun Signal 
11:69. 
Supinski GS, Callahan LA (2006). Caspase activation contributes to endotoxin-induced 
diaphragm weakness. J Appl Physiol 100:1770-1777. 
Supinski GS, Vanags J, Callahan LA (2009). Effect of proteasome inhibitors on endotoxin-
induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 296:L994-L1001. 
Testelmans D, Crul T, Maes K, Agten A, Crombach M, Decramer M, Gayan-Ramirez G 
(2010). Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur 
Respir J 35:549-556. 
Tischler ME, Desautels M, Goldberg AL (1982). Does leucine, leucyl-tRNA, or some 
metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac 
muscle? J Biol Chem 257:1613-1621. 
Toledo M, Busquets S, Sirisi S, Serpe R, Orpi M, Coutinho J, Martinez R, Lopez-Soriano FJ, 
Argiles JM (2011). Cancer cachexia: physical activity and muscle force in tumour-bearing 
rats. Oncol Rep 25:189-193. 
Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, Gosselink R (2010). 
Resistance training prevents deterioration in quadriceps muscle function during acute 
exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
181:1072-1077. 
Urtreger AJ, Diament MJ, Ranuncolo SM, Del C, V, Puricelli LI, Klein SM, De Kier Joffe 
ED (2001). New murine cell line derived from a spontaneous lung tumor induces 
paraneoplastic syndromes. Int J Oncol 18:639-647. 
van Hees HW, Li YP, Ottenheijm CA, Jin B, Pigmans CJ, Linkels M, Dekhuijzen PN, 
Heunks LM (2008). Proteasome inhibition improves diaphragm function in congestive heart 
failure rats. Am J Physiol Lung Cell Mol Physiol 294:L1260-L1268. 
van HH, Ottenheijm C, Ennen L, Linkels M, Dekhuijzen R, Heunks L (2011). Proteasome 
inhibition improves diaphragm function in an animal model for COPD. Am J Physiol Lung 
Cell Mol Physiol 301:L110-L116. 
Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, Butler-Browne G, 
Puymirat J, Gourdon G, Furling D (2010). Progressive skeletal muscle weakness in transgenic 
mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome 
pathway. Neuromuscul Disord 20:319-325. 
Vogiatzis I, Simoes DC, Stratakos G, Kourepini E, Terzis G, Manta P, Athanasopoulos D, 
Roussos C, Wagner PD, Zakynthinos S (2010). Effect of pulmonary rehabilitation on muscle 
remodelling in cachectic patients with COPD. Eur Respir J 36:301-310. 
von HS, Anker SD (2010). Cachexia as a major underestimated and unmet medical need: 
A
cc
ep
te
d 
A
rti
cl
e
Muscle biology, structure, and function in cachexia 
 
30 
 
facts and numbers. J Cachexia Sarcopenia Muscle 1:1-5. 
Wahl C, Liptay S, Adler G, Schmid RM (1998). Sulfasalazine: a potent and specific inhibitor 
of nuclear factor kappa B. J Clin Invest 101:1163-1174. 
Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, 
Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, 
Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM 
(2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. 
Biochem Biophys Res Commun 300:965-971. 
Xue H, Sawyer MB, Wischmeyer PE, Baracos VE (2011). Nutrition modulation of 
gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical 
strategy. JPEN J Parenter Enteral Nutr 35:74-90. 
Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet 
WS, Lacey DL, Goldberg AL, Han HQ (2010). Reversal of cancer cachexia and muscle 
wasting by ActRIIB antagonism leads to prolonged survival. Cell 142:531-543. 
 
 
 
 
 
 
FIGURE LEGENDS 
Figure 1: Rate of body weight gain of mice from LC cachectic mice (open squares) and those 
treated with the proteasome (open circles), NF-κB (asterisks), and MAPK (black circles) 
inhibitors and corresponding control animals (black triangles) over the study period (1 month, 
N=10/group, all groups). Pharmacological agents were always administered on day 15 after 
inoculation of the LP07 cells. 
 
Figure 2: 
A) Mean values and standard deviation of tyrosine release (nmol/mg/2h) in diaphragm 
(white bars) and gastrocnemius (black bars) muscles (expressed in Mean values and 
standard deviation). Statistical significance is represented as follows: i) †††: p<0.001 
and ††: p<0.01 levels in muscles between LC cachectic and control mice and ii) **: 
p<0.01 and *: p<0.05 levels in muscles between any group of LC cachectic mice 
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treated with each of the inhibitors and the LC cachectic animals without any 
pharmacological treatment (N=10/group, all groups). The dashed line separates both 
types of comparisons between the groups.  
B) Mean values and standard deviation of the ubiquitin conjugating enzyme E214κ in 
diaphragm (white bars) and gastrocnemius (black bars) muscles, as measured by 
optical densities in arbitrary units (OD, a.u.). For statistical analysis purposes, the 
following number of animals was used in each group: control (N=6), LC cachexia 
(N=8), LC cachexia animals treated with proteasome inhibitor (N=6), LC cachexia 
mice treated with NF-κB inhibitor (N=8), and LC cachexia rodents treated with 
MAPK inhibitor (N=8). Statistical significance is represented as follows: i) n.s.: non-
significant and †: p<0.05 levels in muscles between LC cachectic and control mice 
and ii) n.s.: non-significant, ***: p<0.001, **: p<0.01 and *: p<0.05 levels in muscles 
between any group of LC cachectic mice treated with each of the inhibitors and the 
LC cachectic animals without any pharmacological treatment. The dashed line 
separates both types of comparisons between the groups.  
C) Mean values and standard deviation of 20S proteasome subunit C8 (top panel) and 
total ubiquitinated proteins (bottom panel) in diaphragm (white bars) and 
gastrocnemius (black bars) muscles as measured by optical densities in arbitrary units 
(OD, a.u.). For statistical analysis purposes, the following number of animals was used 
in each group: control (N=6), LC cachexia (N=8), LC cachexia animals treated with 
proteasome inhibitor (N=6), LC cachexia mice treated with NF-κB inhibitor (N=8), 
and LC cachexia rodents treated with MAPK inhibitor (diaphragm, N=7; 
gastrocnmeius, N=8). Statistical significance is represented as follows: i) n.s.: non-
significant, †††: p<0.001, and †: p<0.05 levels in muscles between LC cachectic and 
control mice and ii) n.s.: non-significant, ***: p<0.001, **: p<0.01, and *: p<0.05 
levels in muscles between any group of LC cachectic mice treated with each of the 
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inhibitors and the LC cachectic animals without any pharmacological treatment. The 
dashed line separates both types of comparisons between the groups.  
Figure 3: 
A) Mean values and standard deviation of NF-κB p50 (top panel) and NF-κB p-p50 
(bottom panel) in diaphragm (white bars) and gastrocnemius (black bars) muscles as 
measured by optical densities in arbitrary units (OD, a.u.). For statistical analysis 
purposes, the following number of animals was used in each group: control (N=6), LC 
cachexia (N=8), LC cachexia animals treated with proteasome inhibitor (N=6), LC 
cachexia mice treated with NF-κB inhibitor (NF-κB p50, N=8; NF-κB p-p50, 
diaphragm N=7; gastrocnemius N=9), and LC cachexia rodents treated with MAPK 
inhibitor (NF-κB p50, N=8; NF-κB p-p50, diaphragm N=8; gastrocnemius N=9). 
Statistical significance is represented as follows: i) †: p<0.05 levels in muscles 
between LC cachectic and control mice and ii) n.s.: non-significant, ***: p<0.001, **: 
p<0.01, and *: p<0.05 levels in muscles between any group of LC cachectic mice 
treated with each of the inhibitors and the LC cachectic animals without any 
pharmacological treatment. The dashed line separates both types of comparisons 
between the groups.  
B) Mean values and standard deviation of NF-κB p65 (top panel) and NF-κB p-p65 
(bottom panel) in diaphragm (white bars) and gastrocnemius (black bars) muscles as 
measured by optical densities in arbitrary units (OD, a.u.). For statistical analysis 
purposes, the following number of animals was used in each group: control (N=6), LC 
cachexia (N=8), LC cachexia animals treated with proteasome inhibitor (N=6), LC 
cachexia mice treated with NF-κB inhibitor (N=8), and LC cachexia rodents treated 
with MAPK inhibitor (N=8). Statistical significance is represented as follows: i) †: 
p<0.05 levels and n.s.: non-significant in muscles between LC cachectic and control 
mice and ii) n.s.: non-significant, ***: p<0.001, and *: p<0.05 levels in muscles 
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between any group of LC cachectic mice treated with each of the inhibitors and the 
LC cachectic animals without any pharmacological treatment. The dashed line 
separates both types of comparisons between the groups.  
C) Mean values and standard deviation IκBα (top panel) and p-IκBα (bottom panel) in 
diaphragm (white bars) and gastrocnemius (black bars) muscles as measured by 
optical densities in arbitrary units (OD, a.u.). For statistical analysis purposes, the 
following number of animals was used in each group: control (N=6), LC cachexia 
(N=8), LC cachexia animals treated with proteasome inhibitor (N=6), LC cachexia 
mice treated with NF-κB inhibitor (IκBα, N=8; p-IκBα, diaphragm N=7; 
gastrocnemius N=8), and LC cachexia rodents treated with MAPK inhibitor (N=8). 
Statistical significance is represented as follows: i) ††: p<0.01 and †: p<0.05 levels in 
muscles between LC cachectic and control mice and ii) ***: p<0.001, **: p<0.01, *: 
p<0.05, and n.s.: non-significant, levels in muscles between any group of LC cachectic 
mice treated with each of the inhibitors and the LC cachectic animals without any 
pharmacological treatment. The dashed line separates both types of comparisons 
between the groups.  
D) Mean values and standard deviation of NF-κB transcriptional activity expressed as the 
ratio to control gastrocnemius muscles as measured by optical densities in arbitrary 
units (OD, a.u.). Statistical significance is represented as follows: i) ††: p<0.01 levels 
in muscles between LC cachectic and control mice and ii) *: p<0.05 and n.s.: non-
significant levels in muscles between any group of LC cachectic mice treated with 
each of the inhibitors and the LC cachectic animals without any pharmacological 
treatment (N=10/group, all groups). The dashed line separates both types of 
comparisons between the groups. 
Figure 4:  
A) Mean values and standard deviation of myostatin (top panel) and myogenin (bottom 
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panel) in diaphragm (white bars) and gastrocnemius (black bars) muscles. For 
statistical analysis purposes, the following number of animals was used in each group:  
control (N=6), LC cachexia (N=8), LC cachexia animals treated with proteasome 
inhibitor (N=6), LC cachexia mice treated with NF-κB inhibitor (myostatin, N=9; 
myogenin, N=8), and LC cachexia rodents treated with MAPK inhibitor (myostatin, 
N=9; myogenin, diaphragm N=8; gastrocnemius N=7). Statistical significance is 
represented as follows: i) ††: p<0.01 and †: p<0.05 levels in muscles between LC 
cachectic and control mice and ii) ***: p<0.001, **: p<0.01, *: p<0.05, and n.s.: non-
significant levels in muscles between any group of LC cachectic mice treated with 
each of the inhibitors and the LC cachectic animals without any pharmacological 
treatment. The dashed line separates both types of comparisons between the groups.  
B) Mean values and standard deviation of myosin heavy chain (MyHC) (top panel) and 
actin (bottom panel) levels in diaphragm (white bars) and gastrocnemius (black bars) 
muscles as measured by optical densities in arbitrary units (OD, a.u.). For statistical 
analysis purposes, the following number of animals was used in each group: control 
(MyHC: diaphragm N=7, gastrocnemius N=6; actin N=6), LC cachexia (N=8), LC 
cachexia animals treated with proteasome inhibitor (N=6), LC cachexia mice treated 
with NF-κB inhibitor (N=8), and LC cachexia rodents treated with MAPK inhibitor 
(MyHC: diaphragm N=8, gastrocnemius N=9; actin, N=8). Statistical significance is 
represented as follows: i) ††: p<0.01 and †: p<0.05 levels in muscles between LC 
cachectic and control mice and ii) ***: p<0.001, *: p<0.05, and n.s.: non-significant 
levels in muscles between any group of LC cachectic mice treated with each of the 
inhibitors and the LC cachectic animals without any pharmacological treatment. The 
dashed line separates both types of comparisons between the groups.  
Figure 5: Mean values and standard deviation of the autophagy protein LC3-II/LC3-I in 
diaphragm (white bars) and gastrocnemius (black bars) muscles as measured by optical 
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densities in arbitrary units (OD, a.u.). For statistical analysis purposes, the following number 
of animals was used in each group: control (N=6), LC cachexia (N=8), LC cachexia animals 
treated with proteasome inhibitor (N=6), LC cachexia mice treated with NF-κB inhibitor 
(diaphragm, N=8; gastrocnemius, N=9), and LC cachexia rodents treated with MAPK 
inhibitor (diaphragm, N=8; gastrocnemius, N=9). Statistical significance is represented as 
follows: i) †: p<0.05 levels in muscles between LC cachectic and control mice and ii) **: 
p<0.01, *: p<0.05, and n.s.: non-significant levels in muscles between any group of LC 
cachectic mice treated with each of the inhibitors and the LC cachectic animals without any 
pharmacological treatment. The dashed line separates both types of comparisons between the 
groups. 
Figure 6: 
A) Representative examples obtained from the diaphragm muscle of the different study 
groups of animals. Myofibers positively stained with the anti-MyHC type II antibody 
are stained in brown color (x 400). Type I fibers are represented in white color (not 
stained).  
B) Representative examples obtained from the gastrocnemius muscle of the different 
study groups of animals. Myofibers positively stained with the anti-MyHC type II 
antibody are stained in brown color (x 400). Type I fibers are represented in white 
color (not stained).  
C) Representative examples of nuclei positively (arrows) and negatively stained for the 
TUNEL assay in the diaphragm muscles of the different study groups of mice (x 400). 
Negative nuclei appear in blue (hematoxylin counterstaining), while TUNEL-positive 
nuclei are brown.  
D) Representative examples of nuclei positively (arrows) and negatively stained for the 
TUNEL assay in the gastrocnemius muscles of the different study groups of mice (x 
400). Negative nuclei appear in blue (hematoxylin counterstaining), while TUNEL-
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positive nuclei are brown.  
Table 1. Physiological characteristics in mice from all groups at the end of the study period (day 30) 
 
 
   Lung cancer cachexia 
 
Control LC 
cachexia p 
Proteasome 
inhibitor p 
NF-κβ 
inhibitor p 
MAPK 
inhibitor p 
Body weight gain (%) +8.97 (2.72) -7.69 (12.89) ††† -11.72 (8.14) n.s. +0.42 (7.26) ** -0.30 (5.59) ** 
Diaphragm weight (g) 0.089 (0.009) 0.067 (0.012) ††† 0.071 (0.01) n.s. 0.08 (0.007) *** 0.076 (0.009) * 
Gastrocnemius weight (g) 0.114 (0.008) 0.087 (0.016) ††† 0.086 (0.009) n.s. 0.101 (0.01) *** 0.094 (0.009) * 
Limb strength gain (%) +10.27 (19.59 ) -11.7 (15.37) ††† -12.2 (24.04) n.s. +3.04 (12.9) ** +0.49 (9.27) *** 
Sc. Tumor weight (g) 
- 1.42 (0.59) - 1.17 (0.56) * 1.03 (0.31) ** 0.57 (0.32) *** 
 
Variables are presented as mean (SD). 
Definition of abbreviations: LC, Lung Cancer; NF-κB, Nuclear Factor-κB; MAPK, Mitogen-
activated protein kinases; Sc., subcutaneous. 
Statistical significance: †††, p≤0.001 between LC cachectic and control mice; n.s., non-significant,* p≤0.05, **, 
p≤0.01 and ***, p≤0.001 between any of the treated mouse groups with cachexia and LC cachexia only animals. 
Grey shades have been used to highlight the significant comparisons between the different groups.  
Table 2. Structural and cellular markers in respiratory and limb muscles of all study groups of animals 
 
                     Lung cancer cachexia 
              Muscle Control LC cachexia p Proteasome inhibitor p 
NF-κB 
inhibitor p 
MAPK 
inhibitor p 
Fiber type composition 
Diaphragm 9.04 (2.05) 8.22 (2.61) n.s. 8.59 (1.37) n.s. 8.12 (1.02) n.s. 6.64 (1.89) n.s. Type I fibers 
(%) Gastrocnemius 13.4 (2.74) 13.17 (2.61) n.s. 11.94 (2.97) n.s. 14.3 (2.35) n.s. 14.5 (2.97) n.s. 
Diaphragm 90.96 (2.05) 91.78 (2.61) n.s. 91.41 (1.37) n.s. 91.98 (1.02) n.s. 93.4 (1.89) n.s. Type II fibers 
(%) Gastrocnemius 86.6 (2.74) 86.83 (2.98) n.s. 88.06 (2.97) n.s. 85.7 (2.35) n.s. 85.5 (2.97) n.s. 
Diaphragm 326.1 (66.59) 233.4 (33.54) †† 320.8 (66) ** 237 (83.71) n.s. 280 (28.9) ** Type I fibers 
area (µm2) Gastrocnemius 951.7 (109.7) 658.8 (122.6) ††† 824.6 (88.7) ** 754.7 (98.8) n.s. 792.5 (102) * 
Diaphragm 382.5 (82.7) 297.1 (68) † 319.9 (66.5) n.s. 297.1 (68) n.s. 291 (35.3) n.s. Type II fibers 
area (µm2) Gastrocnemius 919.2 (135.1) 723.5 (143.9) † 764 (93.8) n.s. 742.9 (121.5) n.s. 793 (91.3) n.s. 
Muscle abnormalities 
Diaphragm 8.16 (1.43) 14.61 (3.75) ††† 11.97 (3.16) n.s. 11.56 (3.9) n.s. 13.1 (2.81) n.s. Abnormal 
fraction (%) Gastrocnemius 3.93 (1.48) 8.15 (1.8) ††† 8.39 (2.18) n.s. 7.05 (1.3) n.s. 4.93 (1.21) *** 
Diaphragm 3.75 (0.62) 6.51 (1.54) ††† 5.18 (1.03) * 4.67 (1.78) * 4.66 (1.1) ** Inflamatory 
cells (%) Gastrocnemius 2.22 (0.99) 5.45 (1.78) ††† 4.91 (1.14) n.s. 3.52 (0.63) ** 2.78 (0.88) *** 
Diaphragm 4.01 (1.44) 7.18 (3.5) † 6.38 (2.79) n.s. 6.11 (1.9) n.s. 7.88 (1.47) n.s. Internal 
nuclei (%) Gastrocnemius 1.59 (0.68) 2.36 (0.8) † 3.28 (0.98) * 3.25 (1.07) * 2.08 (0.69) n.s. 
Diaphragm 46.08 (8.55) 67.85 (10.62) ††† 60.9 (17.93) n.s. 64.1 (11.86) n.s. 60.2 (6.57) * TUNEL-
stained 
nuclei (%) Gastrocnemius 49.71 (12.93) 69.88 (12.62) ††† 70.77 (9.74) n.s. 64.09 (10.4) n.s. 70.7 (9.47) n.s. 
 
Variables are presented as mean (SD). 
Definition of abbreviations: LC, Lung Cancer; NF-κB, Nuclear Factor-κB; MAPK, Mitogen-activated protein kinases; µm; 
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micrometer.   
Statistical significance: n.s., non-significant, †, p≤0.05, ††≤0.01 and †††, p≤0.001 between LC cachectic and control mice; n.s., 
non-significant, * p≤0.05, **, p≤0.01 and ***, p≤0.001 between any of the treated mouse groups with cachexia and LC 
cachexia only animals.  
Grey shades have been used to highlight the significant comparisons between the different groups.  
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